Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Lloyds, AstraZeneca, BATs, Rolls-Royce: What's on the menu for 2024?

Published 19/12/2023, 12:00
Updated 19/12/2023, 12:45
© Reuters.  Lloyds, AstraZeneca, BATs, Rolls-Royce: What's on the menu for 2024?

Proactive Investors - For investors, the focus in 2024 will be on navigating a year expected to be split into distinct halves. That, at least, is the conclusion of Liberum, the boutique investment bank, in assessing the tactics to deploy over the next 12 months.

In the first half, defensive stocks are predicted to outperform - so those are sectors such as healthcare and food, beverages, and tobacco.

This is attributed to a period of economic slowdown and profit pressures. Companies with characteristics such as low volatility compared to the market (low beta), less debt compared to their equity (low debt-to-equity ratios), and significant earnings in foreign currencies are expected to fare better.

Going defensive

Noteworthy picks in the FTSE 100 include AstraZeneca PLC (LON:AZN), British American Tobacco PLC (LON:BATS), and Smith & Nephew PLC (LON:SN), all belonging to sectors likely to demonstrate resilience in tougher economic times.

In the smaller company categories - the FTSE 250 and small-cap stocks - firms such as Darktrace PLC (LON:DARK), Tate & Lyle PLC (LON:TATE), and Oxford Instruments PLC (LON:OXIG) are highlighted for their potential robust performance against a challenging economic backdrop.

For the latter half of 2024, Liberum's focus shifts to cyclical and value stocks. These are stocks of companies that tend to follow the economic cycle of expansion and contraction but are currently undervalued.

The anticipation of economic acceleration and possible interest rate cuts by central banks positions these stocks for potential rallies.

As such, Liberum's analysis underscores the necessity for active portfolio management throughout 2024.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Hardy perennials

The predicted stock market volatility and the division of the year into two distinct phases warrant a flexible and vigilant investment approach.

Additionally, there are companies expected to perform well throughout the entire year, such as British American Tobacco and London Stock Exchange Group PLC (LON:LSEG) in the FTSE 100 and TP ICAP (LON:NXGN) and PZ Cussons (LON:PZC) in the FTSE 250.

These businesses are noted for their international earnings, conservative financial structure, and attractive valuation compared to their worth before the pandemic.

Read more on Proactive Investors UK

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.